Herriot Tabuteau, M.D., is a distinguished leader in the biopharmaceutical industry, currently serving as the Chief Executive Officer, President, and Chairman of the Board at Axsome Therapeutics Inc. Dr. Tabuteau founded Axsome in 2012 with a vision to develop innovative therapies for central nervous system (CNS) disorders. His leadership has been instrumental in guiding the company through the development and commercialization of groundbreaking treatments. Prior to founding Axsome, Dr. Tabuteau held various roles at major pharmaceutical companies, including positions at Purdue Pharma and Organon, where he honed his expertise in clinical development and strategic planning. Dr. Tabuteau's professional journey is marked by significant achievements, particularly in the realm of CNS therapeutics. He earned his medical degree from the University of Pennsylvania School of Medicine and completed his residency in psychiatry at Columbia University and New York State Psychiatric Institute. His clinical and research experience has been pivotal in driving Axsome's mission to address unmet medical needs in areas such as depression, Alzheimer's disease, and pain management. Under his stewardship, Axsome has successfully advanced several drug candidates through clinical trials and secured regulatory approvals, notably for Auvelity, a novel treatment for major depressive disorder. As CEO, President, and Chairman of the Board, Dr. Tabuteau plays a crucial role in shaping Axsome's strategic direction and fostering a culture of innovation. His hands-on approach and deep understanding of both the scientific and business aspects of drug development have been key to the company's growth and success. Dr. Tabuteau's leadership extends beyond the company, as he is actively involved in industry associations and advocates for advancements in CNS research. His commitment to improving patient outcomes continues to drive Axsome's efforts to bring transformative therapies to market.